ERNA — Ernexa Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapSucker Stock

Annual cashflow statement for Ernexa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-4.42	-122	-24.6	-21.7	-44.5
Depreciation
Non-Cash Items	-0.307	101	-0.268	3.29	30.5
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-1.08	-2.35	3.71	-2.12	-1.98
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-3.89	-23.5	-21	-20.4	-15.8
Capital Expenditures	-0.266	-0.154	-0.297	-0.019	-0.369
Purchase of Fixed Assets
Software Development Costs
Other Investing Cash Flow Items	1.23	-22.6	0.25	0	0.004
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Cash from Investing Activities	0.96	-22.7	-0.047	-0.019	-0.365
Financing Cash Flow Items	-0.049	—	-0.116	-0.251	3.72
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	0.291	61.6	19.6	16.6	6.26
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-2.63	15.4	-1.44	-3.87	-9.94